关注
Zaid Taha
Zaid Taha
University of Ottawa, Ottawa Hospital Research Institute
在 ohri.ca 的电子邮件经过验证
标题
引用次数
引用次数
年份
The Hippo pathway: immunity and cancer
Z Taha, H J. Janse van Rensburg, X Yang
Cancers 10 (4), 94, 2018
1542018
Characterization of critical determinants of ACE2–SARS CoV-2 RBD interaction
EEF Brown, R Rezaei, TR Jamieson, J Dave, NT Martin, R Singaravelu, ...
International Journal of Molecular Sciences 22 (5), 2268, 2021
362021
Virally programmed extracellular vesicles sensitize cancer cells to oncolytic virus and small molecule therapy
ME Wedge, VA Jennings, MJF Crupi, J Poutou, T Jamieson, A Pelin, ...
Nature communications 13 (1), 1898, 2022
282022
Nanoluciferase complementation-based bioreporter reveals the importance of N-linked glycosylation of SARS-CoV-2 S for viral entry
T Azad, R Singaravelu, Z Taha, TR Jamieson, S Boulton, MJF Crupi, ...
Molecular Therapy 29 (6), 1984-2000, 2021
262021
Implications for SARS-CoV-2 vaccine design: Fusion of spike glycoprotein transmembrane domain to receptor-binding domain induces trimerization
T Azad, R Singaravelu, MJF Crupi, T Jamieson, J Dave, EEF Brown, ...
Membranes 10 (9), 215, 2020
262020
SARS-CoV-2 S1 NanoBiT: A nanoluciferase complementation-based biosensor to rapidly probe SARS-CoV-2 receptor recognition
T Azad, R Singaravelu, EEF Fekete, Z Taha, R Rezaei, R Arulanandam, ...
Biosensors and Bioelectronics 180, 113122, 2021
252021
Antiviral potential of the antimicrobial drug atovaquone against SARS-CoV-2 and emerging variants of concern
ME Carter-Timofte, R Arulanandam, N Kurmasheva, K Fu, G Laroche, ...
ACS infectious diseases 7 (11), 3034-3051, 2021
222021
Single-dose replicating poxvirus vector-based RBD vaccine drives robust humoral and T cell immune response against SARS-CoV-2 infection
S Boulton, J Poutou, NT Martin, T Azad, R Singaravelu, MJF Crupi, ...
Molecular Therapy 30 (5), 1885-1896, 2022
202022
Oncolytic virus driven T-cell-based combination immunotherapy platform for colorectal cancer
MJF Crupi, Z Taha, TJA Janssen, J Petryk, S Boulton, N Alluqmani, ...
Frontiers in Immunology 13, 1029269, 2022
162022
The strategic combination of trastuzumab emtansine with oncolytic rhabdoviruses leads to therapeutic synergy
R Arulanandam, Z Taha, V Garcia, M Selman, A Chen, O Varette, ...
Communications Biology 3 (1), 254, 2020
152020
Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, sensitizes cancer cells to VSVΔ51 oncolytic virotherapy
B Wong, A Bergeron, G Maznyi, K Ng, A Jirovec, HK Birdi, D Serrano, ...
Molecular Therapy 31 (11), 3176-3192, 2023
92023
Identification of FDA-approved bifonazole as a SARS-CoV-2 blocking agent following a bioreporter drug screen
Z Taha, R Arulanandam, G Maznyi, E Godbout, ME Carter-Timofte, ...
Molecular Therapy 30 (9), 2998-3016, 2022
82022
The Hippo pathway: immunity and cancer. Cancers 10
Z Taha, HJ Janse van Rensburg, X Yang
E94, 2018
52018
Engineering Rapalog-Inducible Genetic Switches Based on Split-T7 Polymerase to Regulate Oncolytic Virus-Driven Production of Tumour-Localized IL-12 for Anti-Cancer Immunotherapy
NT Martin, MJF Crupi, Z Taha, J Poutou, JT Whelan, S Vallati, J Petryk, ...
Pharmaceuticals 16 (5), 709, 2023
42023
Vanadyl sulfate-enhanced oncolytic virus immunotherapy mediates the antitumor immune response by upregulating the secretion of pro-inflammatory cytokines and chemokines
N Alluqmani, A Jirovec, Z Taha, O Varette, A Chen, D Serrano, G Maznyi, ...
Frontiers in immunology 13, 1032356, 2022
42022
CRISPR-mediated rapid arming of poxvirus vectors enables facile generation of the novel immunotherapeutic STINGPOX
JT Whelan, R Singaravelu, F Wang, A Pelin, LA Tamming, G Pugliese, ...
Frontiers in Immunology 13, 1050250, 2023
32023
AT cell-targeted multi-antigen vaccine generates robust cellular and humoral immunity against SARS-CoV-2 infection
S Boulton, J Poutou, R Gill, N Alluqmani, X He, R Singaravelu, MJF Crupi, ...
Molecular Therapy-Methods & Clinical Development 31, 2023
22023
Syngeneic mouse model of human HER2+ metastatic breast cancer for the evaluation of trastuzumab emtansine combined with oncolytic rhabdovirus
Z Taha, MJF Crupi, N Alluqmani, F Fareez, K Ng, J Sobh, E Lee, A Chen, ...
Frontiers in Immunology 14, 1181014, 2023
22023
PI3k and Stat3: Oncogenes that are Required for Gap Junctional, Intercellular Communication
M Geletu, Z Taha, PT Gunning, L Raptis
Cancers 11 (2), 167, 2019
22019
Effect of caveolin-1 on Stat3-ptyr705 levels in breast and lung carcinoma cells
M Geletu, Z Taha, R Arulanandam, R Mohan, HH Assi, MG Castro, ...
Biochemistry and Cell Biology 97 (5), 638-646, 2019
22019
系统目前无法执行此操作,请稍后再试。
文章 1–20